Determined to realize a future in which people with cancer live longer and better than ever before

Size: px
Start display at page:

Download "Determined to realize a future in which people with cancer live longer and better than ever before"

Transcription

1 Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JULY

2 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operations, financial results and the financial condition of Syndax Pharmaceuticals, Inc. ( Syndax or the Company ), including financial position, strategy and plans, the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax s product candidates, and Syndax s expectations for liquidity and future operations, are forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax s filings with the U.S. Securities and Exchange Commission, including the Risk Factors sections contained therein. New risks emerge from time to time. It is not possible for Syndax s management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax s expectations. 2

3 Company strategy Entinostat SNDX-6352 anti-csf1r Ab Menin-MLLr inhibitors New molecules Breast Cancer Immunooncology Immuno-oncology Financing & Staffing 3

4 Syndax investment highlights Entinostat Combo with exemestane: Phase 3 PFS data 3Q18 $$B US opportunity Combo with anti-pd-(l)1: Positive data in Mel, NSCLC Ongoing NSCLC, Mel, CRC, TNBC, Ovar trials Multiple data readouts $$$$B US opportunity SNDX-6352 CSF1R antibody: Phase 1 multiple dose study ongoing Broad clinical dev potential Collaboration with AZ s IMFINZI Menin-MLLr inh Onc driver specific: MLLr leukemias IND in 2019 CRC colorectal cancer; NSCLC non-small cell lung cancer; Mel melanoma; TNBC triple negative breast cancer; Ovar ovarian cancer 4

5 Upcoming milestones ENTINOSTAT (Class 1 specific HDAC inhibitor) 2Q18 3Q18 4Q18 1H19 E Complete Phase 3 enrollment; release PFS ENCORE 601 Final data for PD-(L)1 pretx NSCLC, MEL cohorts ENCORE 601 Registration trial decision for melanoma ENCORE 601 Go / No go decision, Stage 1 of MSS CRC cohort ENCORE 602 Report topline TNBC results ENCORE 603 Report topline Ovarian results SNDX-6352 (anti-csf-1r mab) 2Q18 3Q18 4Q18 1H19 MAD trial data presentation (cancer patients) Menin MLLr inhibitor 2Q18 3Q18 4Q18 1H19 File IND and initiate clinical studies 5

6 Entinostat re-sensitizes cancer cells ERα+ Breast Cancer Acquires Hormone Resistance estrogen acquired resistance to hormone therapy estrogen estrogen drives tumor growth sensitive to hormone therapy + entinostat drive tumor growth to hormone therapy ERα+ breast cancer cell ERα+ breast cancer cell 6

7 Phase 2 trial resulted in breakthrough therapy designation Progression-free Survival Overall Survival Progression probability EE: median PFS 4.3 months EP: median PFS 2.3 months Hazard ratio 0.73 (95% CI: 0.50, 1.07) P=0.055 (1-sided) EE = exemestane plus entinostat EP = exemestane plus placebo Survival probability EE: median OS 28.1 months EP: median OS 19.8 months Hazard Ratio 0.59 (95% CI: 0.36, 0.97) P=0.036 (2-sided) ; P=0.018 (1-sided) Months Placebo 31/66 13/33 4/20 5/16 2/11 4/9 0/5 1/4 1/3 1/1 0/0 0/0 0/0 Entinostat 15/64 14/45 11/29 3/174/14 2/10 0/8 0/8 3/8 2/5 0/1 0/1 0/1 (#events / #at risk) Months Placebo 4/66 13/60 12/47 8/35 5/18 1/3 0/0 Entinostat 4/64 5/55 4/49 9/43 3/21 2/9 0/1 (#events / #at risk) Yardley, Denise A., et al. Journal of Clinical Oncology (2013):

8 Phase 3 E2112 PFS data anticipated 3Q18 E2112: Exemestane +/- entinostat Advanced HR+ HER2- BC following SOC progression (Accrual goal: n=600) Exemestane + entinostat (n=300) Randomized, blinded Exemestane + placebo (n=300) Two primary endpoints: PFS and OS E2112 Trial Milestones 4Q17: Final PFS analysis, 1 st interim OS analysis complete 2Q18: 2 nd interim OS analysis complete 3Q18: Expect to Achieve full accrual, share result of PFS analysis 2H18: If PFS positive, File NDA : Early trial completion possible w/may & Nov interim OS analyses Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 8

9 Blockbuster potential as 2 nd /3 rd line First novel MOA in HR+ BC with Phase 3 data since CDK4/6 Leading treatment options HR+, HER2- advanced breast cancer 1 st line hormone Tx 2 nd /3 rd /4 th line hormone Tx Chemo-Tx Anastrozole or letrazole +/- CDK4,6 inhibitor Anastrazole, Faslodex +/- CDK4,6 inhibitor or Afinitorexemestane 34,000 pts Entinostat-exemestane target population Capecitabine, gemcitabine, eribulin Source: DataMonitor 2016 Breast cancer: HR+/HER2- Disease Coverage Report 9

10 ENCORE Clinical Trial Program: Evaluating entinostat s potential to enhance anti-pd-(l)1 efficacy TNBC HR+ BC MEL NSCLC CRC OVAR PD-(L)1 Immune cells Tumor mutational burden (TMB) Nanostring Focused on early signs of efficacy and biomarkers that predict clinical benefit 10

11 ENCORE 601 / KEYNOTE 142 study design Entinostat + KEYTRUDA Phase 1b: Open-label Completed Dose & safety confirmation / biomarker assessment Phase 2: Open-label Ongoing NSCLC PD-1/PD-(L)1 naïve NSCLC Progressed on PD-1/PD-(L)1 Melanoma Progressed on PD-1 Primary endpoint irrecist ORR MSS CRC PD-1/PD-(L)1 naïve MSS CRC - Microsatellite stable colorectal cancer, irrecist immune related response evaluation criteria solid tumors 11

12 PD-1 relapsed/refractory NSCLC cohort ENCORE 601: PD-1 pre-tx NSCLC 76 pts enrolled, first 57 presented at ASCO 6 confirmed responses in total pop (11% ORR; 95% CI:4-21%) 28.6% ORR in significant subset. Median duration of response 4.6 months Acceptable safety profile Further update expected 3Q18 12

13 ENCORE 601 PD-1 relapsed/refractory NSCLC Primary Endpoint: Overall Response Rate = 11% [95% CI (4% - 21%)] 50% 35% Change from baseline (%) 5% -25% -55% -85% Partial response (confirmed) Partial response (unconfirmed) Stable disease Progressive disease Source: Gandhi, L et al ASCO Annual Meeting

14 Differentiated mechanism targets tumor microenvironment (TME) T REG Immune suppressor cells MDSC Entinostat inhibits Myeloid derived suppressor cells (MDSCs) and T-Regulatory cells (Tregs) in the TME Tumor microenvironment CTLA-4 Cytotoxic T-cell PD-1 Entinostat s activity synergizes with PD-(L)1 to activate immune system against cancer checkpoint inhibitors Tumor Cell Tumor surface Hypothesis: Entinostat can reverse resistance to PD-1 antagonists

15 Monocytes identify patients likely to benefit However, before commencing therapy, a strong predictor of progression-free and overall survival in response to anti-pd-1 immunotherapy was the frequency of CD14+CD16 HLA-DRhi monocytes we propose that the frequency of monocytes in PBMCs may serve in clinical decision support. Source: Kreig, C. et al Nature Med; 24(2)

16 Higher baseline associated with clinical benefit Objective Response Objective Response and/or Total time on therapy >24 wks 30 N=6 N=45 30 N=10 N=41 % of live PBMCs N=15 % of live PBMCs N= Source: Gandhi, L et al ASCO Annual Meeting

17 Higher baseline associated with PFS, ORR benefit Monocyte high subset may be ~30% of PD-1 relapsed / refractory NSCLC Source: Gandhi, L et al ASCO Annual Meeting

18 High monocytes correspond to inflamed TME Gene expression in baseline tumor biopsies from a subset of patients (n = 18) associated with peripheral blood monocyte levels Tumor inflammation signature Monocyte-high subset of patients display increased inflamed gene expression signature relative to monocyte-low. Data suggests entinostat is restoring anti-tumor activity of Keytruda in inflamed cancers n = 14 n = 4 TIS - Tumor inflammation signature score assessed with Nanostring PanCancer IO 360TM panel. 18 genes: CCL5, CD8A, STAT1, PDL2, HLA-DQA1, HLA-DRB1,CXCL9, CXCR6, TIGIT, PDL1, HLA-E, CMKLR1, CD27, IDO1, LAG3, CD276, PSMB10, NKG7 Source: Gandhi, L et al ASCO Annual Meeting

19 Patient segmentation common in NSCLC therapy NSCLC Patient Journey by Line of Therapy (US) Biomarkers used to identify responders (EGFR, ALK, PD-(L)1, TMB) Selection may enable entinostat-keytruda to provide meaningful benefit for a subset of 2L / 3L NSCLC Pembro + platinum + pemetrexed 1 st line 2 nd / 3 rd line PDL-1 High PD-(L)1 monotx Platinum doublet PDL-1 Low ~135,000 pts Chemo ~84,000 pts PD-(L)1 monotx ~33% qualify for combo Pembro-entinostat ~30,000 pts Source: Kantar 2016 Treatment Architecture report; Trial Trove, SEER data = in development 19

20 Potential registration path in NSCLC Entinostat s MOA targets immunosuppressive effects in the tumor microenvironment ENCORE 601 provides evidence that entinostat KEYTRUDA combination may benefit patients relapsed or refractory to anti-pd-1 High circulating levels of classical monocytes correspond to an inflamed tumor microenvironment and are associated with an enhanced response to the entinostat KEYTRUDA combination Syndax will continue to monitor results from the ENCORE 601 cohort and initiate a trial(s) to confirm and extend these observations. 20

21 Alternative treatment options needed for melanoma Metastatic melanoma patient journey 1 st L CTLA-4/PD-1 combo PD-1 MonoTx PD-1 MonoTx 2 nd L CTLA-4 MonoTx ORR 11-14% carboplatin, dacarbazine, temozolomide or paclitaxel ORR 4-11% 21

22 PD-1 relapsed/refractory melanoma cohort ENCORE 601: PD-1 pre-tx Melanoma 55 pts enrolled, first 34 presented at ASCO 6 confirmed responses in total population (18% ORR; 95% CI:7-35%) 65% refractory to CTLA-4 and PD-1 18% ORR in this population Median duration of response 9 months Acceptable safety profile Monocyte analysis ongoing Target population: 10,000 15,000 Registration trial decision 4Q18 22

23 Combination may improve anti-tumor effect Pre-clinical evidence that entinostat-nktr-214 combo enhances immune activation and anti-tumor activity presented at AACR 1 Syndax and Nektar collaborate to explore efficacy in patients with melanoma who have previously progressed on anti- PD-1 therapy Source: 1. Wang L et al AACR Annual Meeting

24 May increase anti-tumor effect by modulating immunosuppressive cells Phase 2 Entinostat HD IL-2 RCC 1 data support hypothesis Enrolled 43 metastatic ccrcc pts oral entinostat, q2wk HD IL-2 dosed q8hr (days 1-5,15-19 of 85 day cycle) ORR = 37% (15/41) 95% CI (22-53%) 3 CR (7%); 12 PR (29%) Median PFS = 13.8 mo Median OS = 65.3 mo Progression free survival Progression-Free Survival Proleukin entinostat mpfs 13.8 mo Time at risk (mo) Proleukin Historic mpfs ~ 4 months Source: 1.Pili R et al Clin Cancer Res; 23(23)

25 Unmet need for CTLA-4 and PD-1 treated patients Metastatic melanoma patient journey 1 st L CTLA4/PD-1 combo PD-1 MonoTx PD-1 MonoTx 2 nd L CTLA4 MonoTx ORR 11-14% Entinostat - KEYTRUDA Entinostat NKTR-214 carboplatin, dacarbazine, temozolomide or paclitaxel ORR 4-11% 25

26 Microsatellite stable colorectal cancer cohort ENCORE 601: PD-1 Naïve MSS-CRC Available data from first 16 patients 1 confirmed response (6% ORR; 95% CI: 0-32) Median PFS of 12.3 weeks Duration of response > 7 months Acceptable safety profile Target population: ~17,000 Enrolling 21 additional patients, data 1H19 26

27 ENCORE 602, 603: Data available 1H19 ENCORE 602: TNBC ENCORE 603: Ovarian TECENTRIQ - entinostat dose determination Phase 1b: Open-label BAVENCIO - entinostat dose determination TECENTRIQ + entinostat (n=35) TECENTRIQ + placebo (n=35) Phase 2: Randomized, double-blind BAVENCIO + entinostat (n=80) BAVENCIO + placebo (n=40) Complete enrollment 2Q18 Enrollment completed 2Q18 Phase 2 ENDPOINTS: Primary endpoint - PFS Secondary endpoint - Overall response rate (ORR) Secondary endpoint - Overall survival (OS) 27

28 ENCORE Clinical Trial Program: Evaluating entinostat s potential to enhance anti-pd-(l)1 efficacy PD-(L)1 Immune cells Tumor mutational burden (TMB) Nanostring TNBC HR+ BC NSCLC MEL CRC OVAR Awaiting final Progress Await data Await data Await data phase 2 results

29 SNDX-6352: Anticipate focused Phase 2 POC program High affinity, IgG4 (K D = 4-8 pm) Multiple ascending dose (MAD, solid tumors) ongoing CSF-1 Receptor Ligand binding Dimerisation SNDX-6352 Collaboration in place to broadly study combination with IMFINZI (AZ) Commence work to establish safety of combination in 2Q18 Communicate Phase 2 strategy 2H18 ATP binding Kinase insert Kinase domain P P P P P TAM tumor associated macrophage; CSF-1R colony stimulating factor -1 receptor Source : Ordentlich, P. et al SITC

30 Menin-MLLr program on track for IND Filing 1H19 MLL-r known cause of leukemias (AML, ALL, MLL) Major market incidence: 4,000/yr NPM1 mut also targeted by MLLr inhibitor Estimated at 25-30% of adult AML Other potential indications: MDS, ALL, AML (incl. MLL-PTD AML) CMML and CML Pancreatic Cancer Gain-of-function p53 mutation tumors VTP data presented at AACR MLLr Inhibitor MLL-r = rearrangements of the Mixed Lineage Leukemia (MLL) gene 30

31 Proven ability to build the pipeline Established relationships enhance identification and access to quality assets Clinical development leadership enables competitive advantage 3Q16: UCB SNDX Q17: Allergan/Vitae Business development continues to be a core strength of our business Menin-MLLr inhibitors 31

32 1Q18 financial highlights and 2018 guidance Ticker Cash and short-term investments Common shares O/S SNDX (NASDAQ) As of March 31, 2018 $113.2 million 24.7 million 2018 Operating Expense Guidance Q R&D Total Operating Expenses $15-17 M $60-64 M $20-22 M $78-84 M 32

33 Upcoming milestones ENTINOSTAT (Class 1 specific HDAC inhibitor) 2Q18 3Q18 4Q18 1H19 E Complete Phase 3 enrollment; release PFS ENCORE 601 Final data for PD-(L)1 pretx NSCLC, MEL cohorts ENCORE 601 Registration trial decision for melanoma ENCORE 601 Go / No go decision, Stage 1 of MSS CRC cohort ENCORE 602 Report topline TNBC results ENCORE 603 Report topline Ovarian results SNDX-6352 (anti-csf-1r mab) 2Q18 3Q18 4Q18 1H19 MAD trial data presentation (cancer patients) Menin MLLr inhibitor 2Q18 3Q18 4Q18 1H19 File IND and initiate clinical studies 33

34 Syndax investment highlights Entinostat Combo with exemestane: Phase 3 PFS data 3Q18 $$B US opportunity Combo with anti-pd-(l)1: Positive data in Mel, NSCLC Ongoing NSCLC, Mel, CRC, TNBC, Ovar trials Multiple data readouts $$$$B US opportunity SNDX-6352 CSF1R antibody: Phase 1 multiple dose study ongoing Broad clinical dev potential Collaboration with AZ s IMFINZI Menin-MLLr inh Onc driver specific: MLLr leukemias IND in 2019 CRC colorectal cancer; NSCLC non-small cell lung cancer; Mel melanoma; TNBC triple negative breast cancer; Ovar ovarian cancer 34

35 Thank you. Questions? 35

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 1Q 2018 EARNINGS PRESENTATION MAY 2018 1 Forward-looking statements disclosure This presentation contains

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2017 EARNINGS PRESENTATION MARCH 2018 1 Forward-looking statements disclosure This presentation contains

More information

Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019

Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains

More information

Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017

Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains

More information

Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017

Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking

More information

Reimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before

Reimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 Forward-Looking

More information

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation

More information

Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)

Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation

More information

Wells Fargo Healthcare Conference September 6, 2018

Wells Fargo Healthcare Conference September 6, 2018 Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are

More information

Leerink Immuno-Oncology Roundtable Conference

Leerink Immuno-Oncology Roundtable Conference Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private

More information

Corporate Presentation

Corporate Presentation Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains

More information

NewLink Genetics Corporation

NewLink Genetics Corporation Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking

More information

Five Prime Therapeutics, Inc. Corporate Overview

Five Prime Therapeutics, Inc. Corporate Overview Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities

More information

Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.

Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer. Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation

More information

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018 MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward

More information

CORPORATE PRESENTATION

CORPORATE PRESENTATION CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

More information

More cancer patients are being treated with immunotherapy, but

More cancer patients are being treated with immunotherapy, but Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH

More information

MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018

MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes

More information

Citi s 13 th Annual Biotech Conference September 5, 2018

Citi s 13 th Annual Biotech Conference September 5, 2018 Citi s 13 th Annual Biotech Conference September 5, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they

More information

NewLink Genetics Corporation

NewLink Genetics Corporation Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that

More information

Third Quarter 2015 Earnings Call. November 9, 2015

Third Quarter 2015 Earnings Call. November 9, 2015 Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements

More information

Investor Meetings October 2018

Investor Meetings October 2018 Investor Meetings October 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements

More information

Jefferies 2018 Healthcare Conference. June 6, 2018

Jefferies 2018 Healthcare Conference. June 6, 2018 Jefferies 2018 Healthcare Conference z June 6, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of ongoing

More information

Q Financial Update November 6, 2018 NASDAQ:FPRX

Q Financial Update November 6, 2018 NASDAQ:FPRX Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,

More information

33 rd Annual J.P. Morgan Healthcare Conference. January 2015

33 rd Annual J.P. Morgan Healthcare Conference. January 2015 33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.

More information

NewLink Genetics Corporation

NewLink Genetics Corporation Stifel Healthcare Conference Presentation NewLink Genetics Corporation NASDAQ: NLNK November 13, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements

More information

TARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018

TARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018 NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements

More information

Dawson James Conference

Dawson James Conference Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding

More information

ASCO 2018 Investor Meeting

ASCO 2018 Investor Meeting ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for

More information

Combining HS-110 and anti-pd-1 in NSCLC. September 1, 2015

Combining HS-110 and anti-pd-1 in NSCLC. September 1, 2015 Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking

More information

Merck Oncology Overview ASCO 2017

Merck Oncology Overview ASCO 2017 Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking

More information

Merck Oncology Overview ASCO 2017

Merck Oncology Overview ASCO 2017 Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking

More information

Investor Call. May 19, Nasdaq: IMGN

Investor Call. May 19, Nasdaq: IMGN Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not

More information

LION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology

LION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private

More information

Transforming science into medicine

Transforming science into medicine Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and

More information

National Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.

National Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved. National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.

More information

July, ArQule, Inc.

July, ArQule, Inc. July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical

More information

Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015

Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015 Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are

More information

Corporate Presentation October 2018 Nasdaq: ADXS

Corporate Presentation October 2018 Nasdaq: ADXS Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements

More information

Merck ASCO 2015 Investor Briefing

Merck ASCO 2015 Investor Briefing Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation

More information

Idera Pharmaceuticals

Idera Pharmaceuticals Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning

More information

March Corporate Presentation

March Corporate Presentation March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements

More information

ArQule Jefferies Global Healthcare Conference June 2015

ArQule Jefferies Global Healthcare Conference June 2015 ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning

More information

Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC

Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within

More information

2016 Year-End Results and Conference Call. March 14, 2017

2016 Year-End Results and Conference Call. March 14, 2017 2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform

More information

FORWARD II PROGRAM UPDATE

FORWARD II PROGRAM UPDATE FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,

More information

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical

More information

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016 ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),

More information

Frédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018

Frédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018 Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress

More information

Corporate Presentation September Nasdaq: ADXS

Corporate Presentation September Nasdaq: ADXS Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and

More information

Corporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers

Corporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain

More information

Full Year 2017 Financial Results. February 14, 2018

Full Year 2017 Financial Results. February 14, 2018 Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,

More information

G1 Corporate Overview March 11, 2019

G1 Corporate Overview March 11, 2019 G1 Corporate Overview March 11, 2019 www.g1therapeutics.com NASDAQ: GTHX 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements within the

More information

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

Rexahn Pharmaceuticals Overview

Rexahn Pharmaceuticals Overview Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ

More information

AXL inhibition to prolong life

AXL inhibition to prolong life AXL inhibition to prolong life First-in-class medicines to treat aggressive cancers Jefferies London Healthcare Conference November 15-16 th 2017 Richard Godfrey, CEO 1 Disclaimer Certain statements contained

More information

NASDAQ & TSX: IMV. BIO Investor Forum. October IMV Inc. All rights reserved.

NASDAQ & TSX: IMV. BIO Investor Forum. October IMV Inc. All rights reserved. NASDAQ & TSX: IMV BIO Investor Forum October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations

More information

OncoMed Pharmaceuticals Jefferies Healthcare Conference. Sunil Patel, Chief Financial Officer, SVP, Corp. Development & Finance June 9, 2016

OncoMed Pharmaceuticals Jefferies Healthcare Conference. Sunil Patel, Chief Financial Officer, SVP, Corp. Development & Finance June 9, 2016 OncoMed Pharmaceuticals Jefferies Healthcare Conference Sunil Patel, Chief Financial Officer, SVP, Corp. Development & Finance June 9, 2016 Safe Harbor Statement These slides and accompanying oral presentation

More information

Anti-IL-33 (ANB020) Program

Anti-IL-33 (ANB020) Program Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain

More information

Corporate Presentation March 2016

Corporate Presentation March 2016 Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

More information

Corporate Overview. June 2018 NASDAQ:FPRX

Corporate Overview. June 2018 NASDAQ:FPRX Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

More information

Building a Leading Oncology Franchise

Building a Leading Oncology Franchise ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may

More information

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO Forward-Looking Statements This

More information

REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES

REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,

More information

Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy

Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking

More information

Corporate Overview. June 2017 NASDAQ:FPRX

Corporate Overview. June 2017 NASDAQ:FPRX Corporate Overview June 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

More information

ArQule CorporateUpdate

ArQule CorporateUpdate ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform

More information

Targeting the Tumor Locally

Targeting the Tumor Locally ARMING THE IMMUNE SYSTEM TO FIGHT CANCER Targeting the Tumor Locally September 2017 NASDAQ:ONCS Cautionary Note Regarding Forward-Looking Statements To the extent statements contained in the following

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical

More information

Investor Presentation

Investor Presentation Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance

More information

Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System

Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,

More information

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking

More information

Clinical: Ipilimumab (MDX-010) Update and Next Steps

Clinical: Ipilimumab (MDX-010) Update and Next Steps Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy

More information

Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018

Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions

More information

Targeting the Tumor Locally

Targeting the Tumor Locally ARMING THE IMMUNE SYSTEM TO FIGHT CANCER Targeting the Tumor Locally October 2017 NASDAQ:ONCS Cautionary Note Regarding Forward-Looking Statements To the extent statements contained in the following presentations

More information

Corporate Presentation June Curis, Inc All Rights Reserved

Corporate Presentation June Curis, Inc All Rights Reserved Corporate Presentation June 2018 Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company

More information

Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018

Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation

More information

A Fully Integrated Cancer Company.

A Fully Integrated Cancer Company. A Fully Integrated Cancer Company. Jefferies Global Healthcare Conference June 3, 2014 Robert Mulroy, President and CEO Forward Looking Statements To the extent that statements contained in this presentation

More information

ARIAD Pharmaceuticals, Inc.

ARIAD Pharmaceuticals, Inc. ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the

More information

New Data from Ongoing Melanoma Study and Clinical Development Strategy Update

New Data from Ongoing Melanoma Study and Clinical Development Strategy Update New Data from Ongoing Melanoma Study and Clinical Development Strategy Update Webcast - 29 th / 30 th May 2018 (ASX: IMM, NASDAQ: IMMP) Notice: Forward Looking Statements The purpose of the presentation

More information

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation

More information

Corporate Overview. May 2017 NASDAQ: CYTR

Corporate Overview. May 2017 NASDAQ: CYTR Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY

More information

Calithera Biosciences. January 2019

Calithera Biosciences. January 2019 Calithera Biosciences January 2019 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the

More information

June IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)

June IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our

More information

Revolutionizing the Treatment of Cancer

Revolutionizing the Treatment of Cancer Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results

More information

A Fully Integrated Cancer Company.

A Fully Integrated Cancer Company. A Fully Integrated Cancer Company. Jefferies 2015 Healthcare Conference June 2, 2015 Robert Mulroy, President & CEO Forward Looking Statements To the extent that statements contained in this presentation

More information

For analyst certification and disclosures please see page 5

For analyst certification and disclosures please see page 5 Conference Update June 7, 2017 ASCO 2017 Detailed Presentation Notes Day 5 As part of our ongoing coverage of the 2017 American Society of Clinical Oncology (ASCO) conference, we attended multiple oral

More information

Targeting the genetic and immunological drivers of cancer

Targeting the genetic and immunological drivers of cancer NASDAQ: MRTX Targeting the genetic and immunological drivers of cancer Corporate Presentation April 2019 1 Safe Harbor Statement Certain statements contained in this presentation, other than statements

More information

PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective

PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca

More information

Calithera Biosciences

Calithera Biosciences Calithera Biosciences March 2019 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the Private

More information

Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS

Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability

More information

Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018

Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation

More information

Company Overview. April Rewriting cancer treatment NASDAQ: EPZM

Company Overview. April Rewriting cancer treatment NASDAQ: EPZM Company Overview NASDAQ: EPZM Rewriting cancer treatment Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform

More information

Corporate Overview. July 2016 NASDAQ: CYTR

Corporate Overview. July 2016 NASDAQ: CYTR Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE

More information

NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results

NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,

More information

Corporate Overview. February 2018 NASDAQ: CYTR

Corporate Overview. February 2018 NASDAQ: CYTR Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER

More information